Patient-Reported Outcomes from the CARTITUDE-4 Study Showed

SOMERSET, N.J.--(BUSINESS WIRE)--Dec 11, 2023--

Related Keywords

United States , Italy , New Jersey , American , Roberto Mina , Ciltacabtagene Autoleucel , Ying Huang , Jessie Yeung , Alexandra Ventura , American Cancer Society , Exchange Commission On , Legend Biotech Corporation , American Society Of Hematology Annual Meeting , Clinical Development , European Organisation For Research , Janssen Biotech Inc , Division Of Hematology , University Of Torino , Department Of Molecular Biotechnology , Exchange Commission , American Society Of Clinical Oncology , American Society Of Hematology , Twitter , Corporate Communications Investor Relations , Health Sciences , Linkedin , Biotech Corporation , Legend Biotech , Annual Meeting , Assistant Professor , Molecular Biotechnology , European Organisation , Cancer Quality , Life Questionnaire Core , Multiple Myeloma Symptom , Impact Questionnaire , Cytokine Release Syndrome , Chief Executive Officer , Important Safety , Release Syndrome , Effector Cell Associated Neurotoxicity Syndrome , Macrophage Activation Syndrome , Risk Evaluation , Mitigation Strategy , Nerve Palsies , Janssen Biotech , Prescribing Information , Boxed Warning , Private Securities Litigation Reform Act , Annual Report , Reported Outcomes , Ciltacabtagene Autoleucel Vs Standard , Lenalidomide Refractory Multiple Myeloma , Hematology Annual , Lines Who Received , Single Infusion , Ciltacabtagene Autoleucel As Study Treatment , Updated Efficacy , Multiple Myeloma , Early Relapse , First Line Treatment , Study Comparing , Versus Pomalidomide , Participants With Relapsed , Chimeric Antigen Receptort Cell , Participants With Multiple Myeloma , Statistics About Multiple Myeloma , Accessed Nov , Corporate Communications , Investor Relations , Public Relations , Business Wire , Region ,